# Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

> **NCT03277482** · PHASE1 · TERMINATED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 16 (actual)

## Conditions studied

- Recurrent Gynecological Cancer
- Metastatic Cervical Cancer
- Metastatic Ovarian Cancer
- Metastatic Vaginal Cancer
- Metastatic Vulvar Cancer
- Metastatic Endometrial Cancer
- Recurrent Cervical Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Vaginal Cancer
- Recurrent Vulvar Cancer
- Recurrent Endometrial Cancer

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Tremelimumab
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT03277482
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-06-01
- **Primary completion:** 2022-07-15
- **Final completion:** 2022-07-15
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Expansion cohort was not open
- **Last updated:** 2025-05-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03277482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03277482, "Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03277482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*